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Aim:To report the long-term follow-upof a cohort of adult patientswith LGGpost-operatively
irradiated in one institution, and to identify prognostic factors for progression free survival.
Background:There is little consensus about the optimal treatment for low-grade glioma (LGG),
and the clinicalmanagement of LGG is one of themost controversial areas in neurooncology.
Radiation therapy is one option for treatment of patients with LGG, whereas other options
include postoperative observation.
Materials and methods: Between 1975 and 2005, 180 patients with LGG (WHO II) received post-
operative irradiation after non radical (subtotal or partial) excision. Patients had to be 18
years of age or older, and have histologic proof of supratentorial ﬁbrillary (FA), protoplas-
mic (PA) or gemistocytic astrocytoma (GA). Radiotherapy was given within 3–10 weeks after
surgery. Treatment ﬁelds were localized and included the preoperative tumor volume, with
a 1–2 cm margin, treated to a total dose of 50–60Gy in 25–30 fractions over 5–6 weeks.
Results: Actuarial ten-year progression free survival (APFS) in the whole group was 19%. The
worse prognosis was observed in patients with GA. Ten-year APFS rates for GA, PA and FA
were 10%, 18% and 22%, respectively.
Conclusion: The ﬁndings from our long-term cohort of 180 patients with LGG conﬁrmed byuni- and multivariate analysis demonstrated that only astrocytoma histology signiﬁcantly
determined the prognosis. The best survival was observed in patients with the ﬁbrillary
variant, and the worst for the gemistocytic one.
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Table 1 – Patho-clinical characteristics of 180 adult
patients with LGG.
Characteristics N %
Age (years)
40 and less 79 44
More than 40 101 56
Gender
Male 95 53
Female 85 47
KPSa
60–70 83 46
More than 70 97 54
Seizures
Yes 103 57
No 77 43
TCMb
Yes 61 34
No 119 66
Extent of surgery
Subtotal 126 70
Partial 54 30
Histology
Fibrillary astrocytoma 104 58
Protoplasmic astrocytoma 36 20
Gemistocytic astrocytoma 40 22
Total dose
50Gy 72 40
More than 50Gy 108 60
a Karnofsky’s performance status.142 reports of practical oncology an
1. Background
Low-grade gliomas (LGGs), the World Health Organization
(WHO) grade 2 tumors, account for about 11% of all pri-
mary brain tumors.1 The most common histologic subtypes
of LGG include astrocytomas, oligodendrogliomas, and mixed
oligostrocytomas.2 This terminology is helpful in differenti-
ating LGG from lower or higher grade gliomas that have a
signiﬁcantly different prognosis. Patients with LGG may sur-
vive for relatively long periods, but often (80%) progress to
higher-grade tumors which are invariably fatal to the patient.
Unfortunately, there is little consensus about the optimal
treatment for LGG, and the clinical management of LGG is one
of the most controversial areas in neurooncology.3
Radiation therapy is one option for treatment of patients
with LGG, whereas other options include postoperative obser-
vation. The role of chemotherapy remains undeﬁned.4 In
general, treatment is reserved for patients with symptomatic
residual disease despite optimal surgical resection or for
patients who are suspected to have high risk features. The
current hypothesis is that patients older than forty, with resid-
ual disease, should receive earlier intervention. The basis for
these recommendations is threeprospective studies doneover
the past ten years.5–7
2. Aim
To report the long-term follow-up of a cohort of adult patients
with LGG post-operatively irradiated in one institution, and to
identify prognostic factors for progression free survival.
3. Materials and methods
The study population was derived from neurosurgical centers
which referred patients to theMaria Skłodowska-CurieMemo-
rial Center in Kraków for radiation therapy. Patients had to be
18 years of age or older, and have histologic proof of a supra-
tentorial ﬁbrillary (FA), protoplasmic (PA) and gemistocytic
astrocytoma (GA). Oligodendrogliomas, mixed oligoastrocy-
tomas and other variants were excluded. Central pathology
review was performed at the Department of Neuropathology
of the Jagiellonian University.
Between January 1, 1975 andMay31, 2005, 180 patientswith
LGG received postoperative irradiation. The oldest patient was
64, the youngest 19 years old (median 47 years).
The distribution of patho-clinical characteristics in our
series is given in Table 1.
Radiotherapy was given within 3–10 weeks after surgery.
The 2D technique was used until 1995 when it was replaced by
the 3D-Conformal technique. The treatment ﬁelds were local-
ized and included the preoperative tumor bed with a 1–2 cm
margin treated to a total dose of 50–60Gy (median 56Gy) in
25–30 fractions over 5–6 weeks.
After the completion of therapy (every 4months for 2 years,
every 6 months for 3 years, and yearly thereafter until year
15), patients had a physical examination that included a neu-
rologic examination and CT or MRI scan, or when clinically
indicated.b TCM – tumor crossing midline.
Actuarial 10-year progression free survival (APFS) rates
were calculated from date of surgery, and estimated using the
Kaplan–Meier method and compared using one- or two sided
log rank tests.8,9 Only variables that were identiﬁed as sig-
niﬁcantly (p≤0.05) associated with the end point (APFS) were
considered valid prognostic parameters. The Cox proportional
hazards model was used to assess the strengths of association
of APFS with various histo-clinical characteristics.10
4. Results
The treatment was generally well tolerated, signs and symp-
tomsof increased intracranial pressure occurred in 21 patients
(12%), and resolved with steroid administration.
APFS for all 180 patients is presented in Fig. 1. The 10-year
APFS was of 19%.
Kaplan–Meier estimates of survival by histology are given
in Fig. 2. The 10-year APFS for FA, PA and GA was of 25%,
18% and 9%, respectively. The results of uni- and multivariate
analysis are shown in Tables 2 and 3.
5. Discussion
LGG is a vexing problem. Some patients present with readily
controllable seizures will enjoy years of freedom from tumor
progression without intervention, whereas others progress
rapidly with neurologic decompensation and death.11–14
Although these tumors are grouped together under the cat-
egory of “low-grade glioma”, they are actually an extremely
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Table 2 – Univariate analysis.
Characteristics 10-Year APFS (%) p
Age (years)
40 and less 22
More than 40 16 NSc
Gender
Male 19
Female 19 NS
KPSa
60–70 17
More than 70 23 NS
Seizures
Yes 20
No 16 NS
TCMb
Yes 12
No 22 NS
Extent of surgery
Subtotal 25
Partial 16 NS
Histology
Fibrillary astrocytoma 22
Protoplasmic astrocytoma 18 0.1387
Gemistocytic astrocytoma 10 0.0312
Total dose
50Gy 20
More than 50Gy 16 NS
a Karnofsky’s performance status.
b TCM – tumor crossing midline.
c NS – not signiﬁcant.
Table 3 – Multivariate analysis (Cox’s model).
Characteristics Relative risk p
Histologyhole group of 180 patients with low-grade gliomas (LGGs).
eterogeneous group with a median survival time rang-
ng from 5 to 10 years.15–18 The best treatment policy for
hese tumors is still unclear. Some physicians advocate early
nd extensive surgery, while others tend to postpone treat-
ent until functional deﬁcits are present. Radiotherapy is
rescribed formost patientswith LGG, only the timing of treat-
ent is debated.19–23
Our series of 180 patients with LGG is one of the largest
roups described in the literature, coming from one center.
he patho-clinical features of the present material are sim-
lar to those reported by other authors.5–7,14,24,25 More than
0% of patients had seizures at presentation, the majority of
ur population were in their ﬁfth and sixth decades of age.
he tumor was located predominantly in the frontal lobe in
1% of patients, in the temporal lobe in 39%, in the parietal
obe in 17%, and in the occipital lobe in 3%. Thirty percent
f patients had bulky residual tumor after surgery, in 54%,
arnofsky performance status was more than seventy.Our results with a 10-year APFS of 19% are close to or
lightly worse than results achieved by other authors (Table 4).
t must be emphasized, however, that the literature data
ig. 2 – Actuarial progression-free survival (APFS) by
istology.Fibrillary astrocytoma 1 0.52
Protoplasmic astrocytoma 1.16 0.020
Gemistocytic astrocytoma 2.92
presented in Table 4 refer to patients after both radical and
partial surgery, and that they include as well grade 2 astrocy-
tomas as mixed forms of gliomas and oligodendrogliomas. We
restricted our review only to adult patients with grade 2 astro-
cytoma, according to the WHO classiﬁcation. This may pose
certain interpretative difﬁculties in direct comparison of our
results with those of other authors, including grade 1 glioma
and mixed astro-oligodendroglioma variants. The notorious
difﬁculties with respect to the histologic diagnosis of gliomas
may also be an important cause for differences between study
Table 4 – Results of postoperative irradiation of patients
with LGG.
Author No. of patients 10-Year survival (%)
Janny et al.28 72 26
Scerrati et al.29 34 21
Leighton et al.18 167 41
Pignatti et al.14 288 38
Yeh et al.24 61 34
Durmaz et al.17 52 28
Bauman et al.30 145 32
Schomas et al.31 33 30
Present series 180 19
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results. Interobserver variability in the diagnosis and grading
of gliomas has been well documented. Coons et al. observed
that even with well-deﬁned criteria, expert observers and for-
mal training, the maximal concordance rate achieved was
86%. Distinguishing between oligodendrogliomas and diffuse
astrocytomas is particularly problematic, as is distinguishing
between pure oligodendroglioma and mixed oligoastrocy-
toma. Entities that can confound low-grade classiﬁcation
include pilocytic astrocytoma, pleomorphic xanthoastrocy-
toma, ganglioglioma, and gliosarcoma.33
Several studies have attempted to identify prognostic fac-
tors in LGG. A number of patient and tumor characteristics,
such as age at diagnosis, performance status, histology sub-
type, presence of seizures at diagnosis and extent of resection,
have been proposed as prognostic factors.
In our group, only the histologic subtype was most consis-
tently and signiﬁcantly associated with survival in uni- and
multivariate analysis. In our study, the outcome of patients
with gemistocytic astrocytomas was slightly worse than that
of those with protoplasmic and ﬁbrillary variants, with ten
year APFS rates of 10%, 18% and 22%, respectively. Hazard
ratio for gemistocytic vs. ﬁbrillary variant being of 2.92 means
that death rate of patients presenting with GA was about
three times higher in comparisonwith ﬁbrillary variant. Better
prognosis for ﬁbrillary astrocytoma was conﬁrmed by Ducray,
Durmaz and Piepmeier.13,17,20 Gemistocytic astrocytomas and
a high MIB labeling index have also been related to poor prog-
nosis in LGG.29,32
We found that TCM has not signiﬁcantly inﬂuenced the
prognosis. Ten year APFS was 12% and 22% for TCM (+) and
TCM (−) patients, respectively. Our ﬁndings do not consist
with the results of the EORTC 22845 trial, in which a median
survival time for TCM (+) and TCM (−) characteristics was
3.6 years and 7.9 years, respectively, with a hazard ratio of
1.43.14
In the univariate analysis, the extent of surgery in our
material reached the borderline of signiﬁcance, with a
p-value of 0.0579. There was no statistical difference in sur-
vival between patients who had been treated with subtotal
resection and those who had undergone a partial one. The
10-year APFS for the former group was of 25% compared to
16% for the latter. The role of surgical resection in manage-
ment of patients with LGG has remained controversial. The
theoretical goals of surgical resection in LGG are to improve
neurologic deﬁcits and to minimize the risk of recurrence, or
malignant transformation. The literature is replete with ret-
rospective series analyzing the impact of surgical resection
on patient outcome.3,18,19,26 Keles et al. identiﬁed 30 articles
on LGG published between 1970 and 2000 that incorporated
statistical analyses and addressed the issue of resection. In
order to reduce known biases, they eliminated studies that
included pediatric patients, contained WHO grade 1 astrocy-
toma, or evaluated small numbers of patients (less than 75).
They were left with only ﬁve articles that they deemed as valid
studies, all ofwhichdemonstrated that extent of resectionwas
a statistically signiﬁcant variable in univariate analysis, and in
four out of the ﬁve studies it was a signiﬁcant factor in mul-
tivariate analysis.23 Pignatti et al. argued that good prognosis
of LGG patients having undergone an extensive resection may
not be due to the resection itself but to the limited size andiotherapy 1 7 ( 2 0 1 2 ) 141–145
superﬁcial site of the tumor (thus being accessible to more
extensive surgery). Based on our own experience, we think
that the impact of extent of surgery is difﬁcult to ascertain
due to the inadequate terminology used in surgical reports,
which vary from surgeon to surgeon.
Age is a well-established prognostic factor for survival in
LGG, the prognosis being worse for older patients.7,13,18,25 The
present series has failed to show any signiﬁcant survival ben-
eﬁts for younger patients. A cut-off point at 40 years was
chosen, but in clinical practice, this should not be interpreted
as an absolute cut-off value.
A number of studies concerning LGG found some asso-
ciation between prognosis and signs and symptoms at
presentation. One series observed a favorable outcome in
patients presenting with seizures, other found the perfor-
mance status to be of prognostic signiﬁcance.7,17,18,25,30 The
present study did not reveal a signiﬁcant association between
the described parameters and patient survival.
Radiotherapy has been a mainstay of LGG therapy for
decades, but much controversy has surrounded the radia-
tion dose which should be delivered.27 The EORTC 22844 trial
randomly assigned 379 patients with histologically conﬁrmed
LGG to receive irradiation postoperatively (or post biopsy) with
either 45Gy in 5 weeks or 59.4Gy in 6.6 weeks. The minimum
length of follow-up was 54 months. The conclusion of this
study was that there was no signiﬁcant difference between
the low-dose and high-dose radiation groups as their 5-year
progression-free survival (PFS) values were 47% and 50%.5 In
a similar trial, the North Central Cancer Treatment Group
(NCCTG), the Radiation Therapy Oncology Group (RTOG), and
the Eastern Cooperative Oncology Group (ECOG) randomly
assigned 211 patients to two groups. One hundred and eight
patients received 50.5Gy in 28 fractions and one hundred and
three patients received 64.8 in 36 fractions. There was no dif-
ference in survival or PFS between the two groups. The 2- and
5-year survival in the low-dose radiation group was 94% and
72%, respectively. The 2- and 5-year survival in the high-dose
radiation group was 85% and 64%. Likewise, the PFS at 5 years
was 55% and 52%, respectively.7 In our study, the total dose
was not a prognostic factor for the 10-year APFS, like in the
described trials.
6. Conclusion
The ﬁndings from our study conﬁrmed by uni- and multivari-
ate analysis, demonstrated that only astrocytoma histology is
an important, statistically signiﬁcant prognostic factor for pro-
gression free survival. The best prognosis is for patients with
the ﬁbrillary variant, and the worst for the gemistocytic one.
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